Tetracycline,Metronidazole — Competitive Intelligence Brief

Tetracycline,Metronidazole (Tetracycline,Metronidazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial 30S ribosome (tetracycline); anaerobic DNA/RNA (metronidazole) Infectious Disease Small molecule

Target snapshot

Tetracycline,Metronidazole (Tetracycline,Metronidazole) — Shanghai Jiao Tong University School of Medicine. This combination of tetracycline (a protein synthesis inhibitor) and metronidazole (a nucleic acid damaging agent) works synergistically to kill bacteria and anaerobic microorganisms through dual antimicrobial pathways.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tetracycline,Metronidazole TARGET	Tetracycline,Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Antibiotic combination	Bacterial 30S ribosome (tetracycline); anaerobic DNA/RNA (metronidazole)
loteprednol etabonate/tobramycin opthalmic suspension	loteprednol etabonate/tobramycin opthalmic suspension	Bausch & Lomb Incorporated	marketed	Corticosteroid/Aminoglycoside antibiotic combination	Glucocorticoid receptor (loteprednol); bacterial ribosome 30S subunit (tobramycin)
Pivmecillinam/augmentin	Pivmecillinam/augmentin	Radboud University Medical Center	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Clindamycin + Gentamicin	Clindamycin + Gentamicin	Mercy Health Ohio	marketed	Antibiotic combination (lincosamide + aminoglycoside)	Bacterial ribosome (50S subunit for clindamycin; 30S subunit for gentamicin)
Prednisolone and amoxicillin/clavulanate	Prednisolone and amoxicillin/clavulanate	University of Chicago	marketed	Corticosteroid + Beta-lactam antibiotic combination	Glucocorticoid receptor (prednisolone); Bacterial peptidoglycan cross-linking (amoxicillin); Beta-lactamase (clavulanate inhibition)
Gentamicin + narrow spectrum betalactam	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class